Company Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.
The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation.
The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2009 |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Ryan M. Confer M.S. |
Contact Details
Address: 1601 Trinity Street, Bldg. B, Suite 3.322 Austin, Texas 78712 United States | |
| Phone | 512-537-7997 |
| Website | genprex.com |
Stock Details
| Ticker Symbol | GNPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595248 |
| CUSIP Number | 372446104 |
| ISIN Number | US3724462037 |
| Employer ID | 90-0772347 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Rodney Varner | Co-Founder, Chairman, President and Chief Executive Officer |
| Ryan M. Confer M.S. | Chief Financial Officer |
| David M. Schloss | Senior Vice President of Human Resources |
| Thomas C. Gallagher Esq. | Senior Vice President of Intellectual Property and Licensing |
| Dr. Mark S. Berger M.D. | Chief Medical Officer |
| Dr. Suzanne Thornton-Jones | Senior Vice President of Regulatory Affairs and Quality |
| Dr. Jack A. Roth F.A.C.S., M.D. | Chairman of Scientific and Medical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 8-K | Current Report |
| May 20, 2024 | 424B5 | Filing |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 1, 2024 | 10-K | Annual Report |